

What Providers Need to Know about Monovalent COVID-19 Vaccines: Moderna 2023-2024



National Association of
Pediatric Nurse PractitionersSM
Immunization SIG

COVID-19 vaccines will be covered under Vaccines for Children

Product Overview

Safety and Immunogenicity of Moderna COVID-19 Vaccine (2023-2024 Formula) Monovalent XBB.1.5 Variant Vaccine-5th dose (3rd booster)

- SE: Pain at site, headache, myalgia, fatigue most common (consistent like previous vaccine)
- N:50, 21-94 years, 22% >65 years, 60% women, 10% non-white, 68% prior SARS-CoV-2infection
- XBB.1.5 vaccine with cross neutralization with other circulating variants

Administration

The Moderna COVID-19 Vaccine (2023-2024 Formula) is authorized/approved for all doses administered to individuals 6 months and older to prevent COVID-19. Moderna COVID-19 Vaccine (2023-2024 Formula) is authorized for use as follows:

Individuals **6 months through 4 years** of age:

0.25ml single dose vial

- Unvaccinated individuals: Two doses of Moderna COVID-19 Vaccine (2023-2024 Formula) are administered. The second dose is administered 1 month after the first.
- Individuals who have received one dose of any Moderna COVID-19 Vaccine, including Moderna COVID-19 Vaccine, Bivalent: A single dose of Moderna COVID-19 Vaccine (2023-2024 Formula) is administered 1 month after the previous dose.
- Individuals who have received two or more doses of any Moderna COVID-19 Vaccine, including Moderna COVID-19 Vaccine, Bivalent: A single dose of Moderna COVID-19 Vaccine (2023-2024 Formula) is administered at least 2 months after the last previous dose.
- For children 6 months to 4 years of age COVID vaccines should NOT be interchanged.

Individuals **5 years through 11 years** of age, regardless of vaccination status:

0.25ml single dose vial

- Single dose of Moderna COVID-19 Vaccine (2023-2024 Formula). If previously vaccinated with any COVID-19 vaccine, administer at least 2 months after receipt of the last previous dose of any COVID-19 vaccine.

Immunocompromised individuals 6 months through 11 years of age

- Complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. At least one dose should be with a COVID-19 vaccine (2023-2024 Formula).

Individuals 12 and older

0.5ml single dose vial or pre-filled syringes

- SPIKEVAX (COVID-19 Vaccine, mRNA) (2023-2024 Formula) approved

Resources

- [Moderna - Sept 12 2023 ACIP - 2023-2024 COVID-19 Vaccine AC \(cdc.gov\)](#)
- [Moderna COVID-19 Vaccine | FDA](#)